Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn) A percutaneous absorption type cerebral protective agent comprising, as an active ingredient, 0.1 to 30 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof in a base.

2. (Withdrawn) The percutaneous absorption type cerebral protective agent according to claim 1, wherein the base is an aqueous base.

3. (Withdrawn) The percutaneous absorption type cerebral protective agent according to claim 2, wherein the aqueous base comprises, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

4. (Withdrawn) The percutaneous absorption type cerebral protective agent according to claim 1, wherein the base is a rubber base.

5. (Withdrawn) The percutaneous absorption type cerebral protective agent according to claim 4, wherein the rubber base comprises, based on the total amount of the rubber base, 10 to 50 percent by mass of a rubber polymer, 10 to 50 percent by mass of a plasticizer, and 5 to 50 percent by mass of a tackifier.

6. (Withdrawn) A method of manufacturing a pharmaceutical composition, the method comprising:

combining a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof with a base in an amount of 0.1 to 30 percent by mass.

7. (Withdrawn) The method according to claim 6, wherein the base is an aqueous base.

8. (Withdrawn) The method according to claim 7, wherein the aqueous base comprises, based on a total amount of the aqueous base, 1 to 20 percent by mass of a water-soluble polymer, 0.01 to 20 percent by mass of a cross-linking agent, 10 to 80 percent by mass of polyhydric alcohol, and 1 to 80 percent by mass of water.

9. (Withdrawn) The method according to claim 6, wherein the base is a rubber base.

10. (Withdrawn) The method according to claim 9, wherein the rubber base comprises, based on the total amount of the rubber base, 10 to 50 percent by mass of a rubber polymer, 10 to 50 percent by mass of a plasticizer, and 5 to 50 percent by mass of a tackifier.

11. (Currently Amended) A method of protecting against cerebral dysfunction, comprising:

administering to a patient a percutaneous absorption type pharmaceutical

composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof,

the active ingredient being present in an amount of 0.1 to 30 percent by mass in ~~a base~~ an aqueous base, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of water.

12–15. (Canceled)

16. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises n-methyl-2-pyrrolidone or crotamiton as a dissolving agent.

17. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

18. (New) The method according to claim 16, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

19. (New) The method according to claim 16, wherein the dissolving agent is crotamiton.

20. (New) The method according to claim 19, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.